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Breast cancer stem cellGanglioside GD2 is highly expressed on neuroectoderm-derived tumors and sarcomas, including
neuroblastoma, retinoblastoma, melanoma, small cell lung cancer, brain tumors, osteosarcoma,
rhabdomyosarcoma, Ewing’s sarcoma in children and adolescents, as well as liposarcoma, ﬁbrosar-
coma, leiomyosarcoma and other soft tissue sarcomas in adults. Since GD2 expression in normal
tissues is restricted to the brain, which is inaccessible to circulating antibodies, and in selected
peripheral nerves and melanocytes, it was deemed a suitable target for systemic tumor immuno-
therapy. Anti-GD2 antibodies have been actively tested in clinical trials for neuroblastoma for over
the past two decades, with proven safety and efﬁcacy. The main limitations have been acute pain
toxicity associated with GD2 expression on peripheral nerve ﬁbers and the inability of antibodies
to treat bulky tumor. Several strategies have been developed to reduce pain toxicity, including
bypassing complement activation, using blocking antibodies, or targeting of O-acetyl-GD2 derivative
that is not expressed on peripheral nerves. To enhance anti-tumor efﬁcacy, anti-GD2 monoclonal
antibodies and fragments have been engineered into immunocytokines, immunotoxins, antibody
drug conjugates, radiolabeled antibodies, targeted nanoparticles, T-cell engaging bispeciﬁc antibod-
ies, and chimeric antigen receptors. The challenges of these approaches will be reviewed to build a
perspective for next generation anti-GD2 therapeutics in cancer therapy.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Aberrant glycosylation is a hallmark of malignant cellular trans-
formation [1]. Several tumor associated carbohydrate antigens
have been shown to be involved with tumor proliferation, invasion,
angiogenesis, metastasis and immunity. One such antigen is the
ganglioside GD2, which is highly expressed on neuroectoderm-derived
tumors and sarcomas, including neuroblastoma, retinoblastoma,
melanoma, small cell lung cancer, brain tumors, osteosarcoma,
rhabdomyosarcoma, Ewing’s sarcoma in children and adolescents, as
well as liposarcoma, ﬁbrosarcoma, leiomyosarcoma and other soft
tissue sarcomas in adults [2–4]. More recently, several research
laboratories reported the presence of surface GD2 on breast cancer
stem cells [5,6], as well as on neuroectodermal [7] and mesenchy-
mal stem cells [8,9].
Gangliosides are sialic acid-containing glycosphingolipids that
play important roles in signal transduction as well as cell adhesion
and recognition [10]. GD2 is a b-series ganglioside that requires the
enzymes GD3 synthase and GD2 synthase to add sialic acid units
onto its precursor GM2 (see Fig. 1). Normal tissues generally ex-
press a-series gangliosides, whereas b-series gangliosides are ex-
pressed during fetal development and are restricted primarily tothe nervous system in healthy adults and at low levels in periphe-
ral nerves and skin melanocytes [11].
As a tumor antigen, GD2 has been shown to enhance tumor
proliferation and invasiveness in small cell lung cancer cells [12]
and osteosarcoma cells [13]. One possible mechanism for this
enhanced proliferative ability of GD2(+) tumor cells was recently
proposed by Cazet et al. [14], who showed that up-regulation of
GD2 in triple negative (ER-, PR-, and Her-) breast cancer cells
led to enhanced proliferation, whereby GD2 directly induced
constitutive activation of the proto-oncogene c-Met. It has also
been recently suggested that GD2 enhanced platelet adhesion to
extracellular matrix collagen by upregulating integrin a2b1-mediated
tyrosine phosphorylation of p125FAK, and promoting metastasis in
neuroblastoma cells [15]. Binding of tumor cells with anti-GD2
monoclonal antibodies (MoAbs) has been shown to interfere
with proliferation and invasiveness, as well as to directly induce
apoptosis [16].
As a potential target for anti-tumor immunotherapy, GD2 is
ideal due to the high expression on several tumor types and re-
stricted expression on normal tissue. In fact, the National Cancer
Institute pilot program for the prioritization of the most important
cancer antigens ranks GD2 as #12 out of 75 potential targets for
cancer therapy based on therapeutic function, immunogenicity,
role of the antigen in oncogenicity, speciﬁcity, expression level
and percent of antigen-positive cells, stem cell expression, number
Fig. 1. (A) Biosynthetic pathway of gangliosides, and (B) chemical structure of GD2.
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topes, and cellular location of antigen expression [17]. GD2 comes
in at #6, when you consider antigens that are directly targetable in
the circulation or on the cell surface. The total US incidence of
GD2-positive tumors is >200000 annually. These cancers have a
high mortality rate (20–80%), where 60–100% (based on tumor
types) are candidates for anti-GD2 immunotherapy.There are two main challenges in creating effective antibody
therapeutics for GD2(+) tumors. The ﬁrst has to do with creating
antibodies of sufﬁcient afﬁnity that can mediate Fc-receptor
dependent killing of the GD2(+) tumors cells. Because the
immune response to glycans generally lacks T-cell help, antibodies
generated towards carbohydrate antigens are often produced as
low afﬁnity IgM antibodies [18], and because of their size, have
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the toxicity related to GD2 expression on normal tissue. While
the blood brain barrier prevents intravenously administered
anti-GD2 MoAbs from entering the central nervous system
(CNS), potential toxicities towards peripheral nerves and melano-
cytes are possible.
Despite these limitations, several anti-GD2 antibodies have
been developed, and four in particular, 3F8, hu3F8, ch14.18 and
hu14.18, have been extensively tested in the clinic (see Table 1
for all anti-GD2 therapeutics currently in clinical trials). These
antibodies have been primarily tested in pediatric neuroblastoma,
a malignancy accounting for 7% of all childhood cancers and 15%
of pediatric cancer deaths (see Cheung et al. [19] for recent re-
view). Nearly all neuroblastoma tumors abundantly express
GD2, estimated at 5–10 million molecules/cell with immunosup-
pressive properties [20]. Acute toxicities of anti-GD2 MoAb
therapy have included hypertension, pain, fever and urticaria,
thought to be related to complement activation [21], although
long-term toxicities have been uncommon [22]. Despite these
side-effects, anti-GD2 MoAb immunotherapy has encountered
few long term side effects among patients followed for up to
20 years.
In this review, we will summarize antibody-engineering
strategies that have been utilized for targeting GD2, including
methods to enhance anti-tumor potency, as well as future
directions.Table 1
Anti-GD2 therapeutics currently in development.
Category Antibody combinations
Naked antibody (3F8 based) 3F8 + allogenic NK cells
3F8 + beta-glucan
3F8 + heat modiﬁed 3F8 + GM-CSF
3F8
3F8 + GM-CSF
3F8 + GM-CSF + beta-glucan + isotretinoin
3F8 (high dose) + GM-CSF + isotretinoin
Naked antibody (hu3F8 based) hu3F8
hu3F8 + GM-CSF
hu3F8 + IL-2
Naked antibody (ch14.18 based) ch14.18 + GM-CSF
ch14.18 + lenalidomide + isotretinoin
ch14.18/CHO + isotretinoin + IL-2 (continuous infu
ch14.18 + GM-CSF + IL-2
ch14.18/CHO + isotretinoin + IL-2 + G-CSF
Naked antibody (hu14.18 based) hu14.18(K332A)
hu14.18(K332A)+IL-2 + GM-CSF + Natural Killer Ce
hu14.18(K332A)+IL-2 + G-CSF + GM-CSF
Naked antibody (others) MORAb028 (human IgM)
8B6 (anti-O-acetyl-GD2)
Antibody cytokine fusion hu14.18-IL2
hu14.18-IL2
hu14.18-IL2 + GM-CSF + isotretinoin
c60C3-IL15
hu3F8-IL15
Radiolabeled antibody 131I-3F8 + GM-CSF + bevacizumab
131I-3F8 and 124I-3F8 (intra-Ommaya)
131I-hu3F8 and 124I-hu3F8
hu3F8 multistep targeting
Antibody for pre-targeting hu3F8 multistep targeting
T-cell engaging bispeciﬁc
antibodies
hu3F8xhuOKT3 BsAb
Chimeric antigen receptor 14G2a-CAR in EBV-CTL (1st generation)
iC9-GD2 (14G2a) CAR transduced T cells (3rd gene
switch)
iC9-GD2 (14G2a) CAR transduced VZV speciﬁc T c
hu3F8-CAR2. Anti-GD2. monoclonal antibodies
2.1. Murine antibodies
3F8 was the ﬁrst anti-GD2 MoAb to be tested in patients with
neuroblastoma [2,23,24]. MoAb 3F8 is a murine IgG3 with the
highest reported afﬁnity for GD2 (KD = 5 nM) [25]. In pre-clinical
studies, 3F8 has been shown to have dose-dependent killing of
neuroblastoma cells by complement-mediated cytotoxicity
(CMC), and by lymphocytes, cultured monocytes, and granulocytes
[22]. 3F8 binds to FccRII and FccRIII for neutrophil- and NK-med-
iated ADCC (antibody-dependent cell-mediated cytotoxicity),
respectively, and the CR3 receptor is also important for cytotoxic-
ity [26,27]. When combined with the cytokine GM-CSF, 3F8
induced a 80% complete response of chemo-resistant NB
metastatic to the bone marrow [28], and >60% long term survival
among high risk stage 4 children with metastatic neuroblastoma
treated in ﬁrst remission [29]. In an effort to reduce the acute tox-
icities of pain, hypertension, fever and urticaria, which limit the
maximum tolerated dose, a new strategy was developed using a
heat-modiﬁed 3F8, which lacks effector functions but may serve
as a blocking agent to de-sensitive peripheral nerves before admin-
istration of therapeutic 3F8 doses. A phase I study showed that this
strategy signiﬁcantly reduced the analgesic requirements for pain
control when compared to historical controls for dose levels
through 80 mg/m2/d [30].Translational
status
NCT identiﬁer
Phase I NCT00877110
Phase I NCT00492167
Phase I NCT00450307
Phase II NCT00002458
Phase II NCT00072358
Phase II NCT00089258
Phase II NCT01183897,
NCT01183884
Phase I NCT01419834
Phase I NCT01757626
Phase I NCT01662804
Phase I NCT01418495
Phase I NCT01711554
sion) Phase I/II NCT01701479
Phase III NCT00026312
Phase III NCT01704716
Phase I NCT00743496
lls Phase I NCT01576692
Phase II NCT01857934
Phase I NCT01123304
Pre-clinical
Phase I NCT00003750
Phase I NCT00082758
Phase II NCT01334515
Pre-clinical
Pre-clinical
Phase I NCT00450827
Phase II NCT00445965
Pre-clinical
Pre-clinical
Pre-clinical
Pre-clinical
Phase I NCT00085930
ration CAR with iCaspase safety Phase I NCT01822652
ell + VZV vaccine Phase I NCT01953900
Pre-clinical
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scribed in the literature, including murine MoAb ME36.1 and
14.G2a, which have lower afﬁnities to GD2 than 3F8 (KD = 19 nM
and KD = 77 nM, respectively) [25].
ME36.1 was originally derived as a mouse IgG3, and class
switched to IgG2a and IgG1 variants [31]. ME36.1 binds predomi-
nantly to GD2, with some cross-reactivity to GD3, which is also
present on several neuroectodermal tumors including melanoma.
Preclinical studies showed that the IgG2a MoAb ME 36.1 signiﬁ-
cantly inhibited tumor growth at the inoculation site as well as
metastatic spread to lymph nodes and lungs [32]. The crystal struc-
ture of the ME36.1 Fab fragment was solved in an effort to human-
ize the antibody, but humanization efforts resulted in weaker
antigen binding [33]. No subsequent work was attempted until
more recent efforts to create bispeciﬁc antibodies based on
ME36.1 (reviewed later).
MoAb 14.G2a is an IgG2a class switch variant of MoAb 14.18,
which was originally isolated as an IgG3 isotype [34,35]. 14.G2a
showed higher in vitro and in vivo ADCC than 14.18, and was sub-
sequently prepared for clinical development. Initial clinical trials of
patients with neuroectodermal tumors found expected toxicities
(pain, urticaria, fever), with limited anti-tumor activity. Subse-
quent studies found that 14.G2a when combined with the cytokine
IL-2, could achieve a modest anti-tumor response [36].
The structures of all three of these well-characterized murine
anti-GD2 MoAbs were recently analyzed based on computational
modeling [37]. Docked models of MoAb:GD2 were generated using
the crystal structure of 3F8 and ME36.1, as well as a homology
model of 14.G2a (see Fig. 2). Electrostatic mapping of the three
antibody CDR binding sites revealed a high degree of positively
charged surface area (from Arg, Lys, and His residues) to interact
with the negatively charged sialic acid residues of GD2. 3F8 and
ME36.1 had much more positively charged surface area relative
to 14.G2a and may explain their higher afﬁnity for GD2. Based
on random mutagenesis of the CDR combined with cell sorting,
we have found that mutations which increase the electrostatic
interaction of 3F8 with GD2 can signiﬁcantly enhance the afﬁnity
without appreciable loss of speciﬁcity (unpublished data).
2.2. Chimeric and humanized antibodies
Despite the pre-clinical anti-tumor effects of anti-GD2 MoAbs
in animal models, clinical studies have shown that when these
antibodies were given to human subjects, the majority developed
a human anti-mouse antibody (HAMA) response, which could
compromise clinical efﬁcacy. For antibody 3F8 trials, patients were
closely followed for their HAMA titer and infusions given only
when HAMA resolved [26]. Nonetheless some patients had to wait
for months before repeat antibody injections could be given. For
these reasons, attempts have been made to create anti-GD2 MoAbsFig. 2. Structural models and binding afﬁnities of murine anti-GD2 monoclonal antibod
antigen binding sites with the VL domain to the left and VH domain to the right. Higher af
of the antigen binding pocket.using chimeric versions of the murine MoAb (where the VH and VL
domain of the murine antibody are grafted onto human IgG con-
stant domains), humanized versions (where just the CDR loops
and a few other structurally signiﬁcant residues of the murine
MoAb are grafted onto a fully human MoAb framework), or by
using fully human MoAbs.
The ﬁrst non-murine anti-GD2 antibody reported was L72, a
fully human IgM, which was an antibody produced in vitro by Ep-
stein–Barr virus (EBV)-transformed lymphoblastoid cell lines
established from peripheral blood lymphocytes of melanoma pa-
tients [38,39]. In a clinical study where L72 was directly injected
into cutaneous melanoma lesions in 8 patients, regression was
seen in all tumors except in those of two patients whose tumors
were shown to have low antigenicity [40]. No subsequent studies
were reported.
MoAb 14.G2awas chimerized to form ch14.18 and humanized to
form hu14.18 (named after the original mouse 14.18 IgG3 isotype)
[41]. Phase I studies of ch14.18 conﬁrmed safety, with severe pain
being the commonadverse effect [42,43]. A recent phase III random-
ized trial showed that ch14.18 when combined with GM-CSF and
interleukin-2, was associatedwith a signiﬁcantly improved survival
in patients with high-risk neuroblastoma compared to standard
therapy after two years of follow-up [44]. Strategies to reduce
antibody-induced pain have focused on reducing complement
activation which had long been thought to be a contributing factor.
Sorkin et al. [45] have shown that reducing complement activation
by making a speciﬁc point mutation K332A in the Fc region of
hu14.18, resulted in a signiﬁcant reduction in antibody inducedpain
in a rat model. Unlike mice, rats express GD2 and serve as a model
for anti-GD2 MoAb induced pain [46,47].
Murine 3F8 was also recently humanized (hu3F8) based on
complementarity determining region (CDR) grafting [25], and is
currently in Phase I trials (clinical trials.gov NCT01419834,
NCT01757626 and NCT01662804). Initial results show reduced
rate of HAHA (human anti-human antibody) response, and inter-
estingly, less pain than comparable doses of the murine 3F8
(unpublished). It has been shown that hu3F8 elicits less comple-
ment activation than murine 3F8 [25], and further supports the
hypothesis that anti-GD2 MoAb induced pain may be complement
mediated.
The positive prognostic impact of HAMA response on patient
outcome, though not intuitive, was consistently observed in
clinical trials of 3F8 [26]. Whether it represents an anti-idiotypic
network [48] or an indirect measure of a host anti-tumor response
remains an interesting question.
2.3. Anti-O-acetyl-GD2 antibody
We had originally observed that in addition to GD2, a GD2-
derivative with a 9-O-acetyl modiﬁcation on the terminal sialicies, adapted from Ahmed et al. [37]. Models are shown as top down views of the
ﬁnities to GD2 are associated with dense areas of positive charge (blue) at the center
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iﬁed 9-O-acetyl-GD2 was also observed in melanoma cells [50].
From a panel of 15 anti-GD2 MoAbs, 13 of them, including 3F8,
bound to both GD2 and 9-O-acetyl GD2 [49]. A recent study by
Alvarez-Rueda [51] investigated the presence of O-acetyl GD2 on
normal tissues, including peripheral nerves using the murine
MoAb 8B6 which only bound O-acetyl-GD2 and not GD2. When
compared to MoAb 14.G2a, 8B6 stained tumor cells but not
peripheral nerves, whereas 14.G2a reacted with both. It was
hypothesized that targeting O-acetyl-GD2 could reduce the acute
toxicities currently associated with anti-GD2 MoAbs. A follow up
paper showed that 8B6 inhibited tumor growth in vitro and in
mouse models, even in the absence of ADCC and CMC, by inducing
cell cycle arrest and apoptosis [52].2.4. Anti-GD2 single chain variable fragments
Single chain variable fragments (scFvs) are generated by fusing
the VH and VL domains of an antibody with a ﬂexible linker into a
single polypeptide chain. 5F11scFv was derived from a murine IgM
and been successfully expressed in bacteria [53] and afﬁnity ma-
tured by phage display [54]. ScFv of 14.18/14.G2a have also been
described [55], and scFv fragments of hu3F8 are currently being
characterized (unpublished). ScFvs are 25 kDa in size and are
amenable for creating recombinant fusion proteins that can be ex-
pressed in bacteria. They can theoretically achieve greater tumor
penetration, but have much shorter serum half-lives than full
length antibodies which persist in the blood for days by utilizing
the neonatal Fc-receptor pathway [56].3. Strategies to enhance antibody efﬁcacy
Several strategies have been developed to enhance the efﬁcacy
of antibody immunotherapy of GD2(+) malignancies and are basedFig. 3. Schematic of anti-GD2 therapeutics. Formats are predominantly based on full le
engineering radiolabeled antibodies, antibody drug conjugates, immunocytokines, immu
arrows). Anti-GD2 scFv fragments have been used to engineer immunotoxins, bispeciﬁc
(blue arrows).on either the full IgG framework, or antibody fragments. The differ-
ent formats are schematized in Fig. 3.
3.1. Immunocytokines
Cytokines such as IL-2 and GM-CSF have been used in combina-
tion with anti-GD2 MoAbs for their ability to multiply the number
and efﬁciency of NK cells and granulocytes that mediate ADCC
[57–60]. The idea to fuse a cytokine directly to a MoAb, termed
an immunocytokine, came about from an effort to enhance the
ADCC of the MoAb by increasing the cytokine concentration in
the tumor microenvironment, and to reduce the systemic toxicities
of free cytokine. IL-2 for example, has been shown to cause
capillary leak syndrome in patients [44]. Despite potential toxicity,
IL-2 has been the lead candidate for anti-GD2 immunocytokines.
This is predicated on the preclinical anti-neuroblastoma effect
of IL-2, and its FDA approval status in the treatment of other
human cancers such as metastatic renal carcinoma and malignant
melanoma (see [61] for review).
IL-2 activates NK, NKT and CD8(+) T-cells, and an anti-GD2/IL-2
immunocytokine was reported by Gillies et al. [62] where IL-2 was
fused to the C-terminus various forms of ch14.18. Three versions
were constructed, where IL-2 was fused to the C-terminus of the
heavy chain CH1 (excluding the CH2 and CH3 domains to create
a monovalent ‘Fab-IL2’), to the C-terminus of CH2 domain (exclud-
ing the CH3 domain, to attempt a bivalent construct termed a
‘CH2-IL2’), and ﬁnally to the C-terminus of the CH3 domain to cre-
ate a fully intact IgG (termed ‘CH3-IL2’). While all three constructs
retained IL-2 activity by standard T-cell proliferation assays, the
Fab-IL2 lost GD2 binding activity (presumably from weak monova-
lent binding of antigen, and the CH2-IL2 construct did not assem-
ble into a bivalent antibody-like complex having an intact hinge
region. Interestingly, the CH3-IL2 was shown to have enhanced
binding to neuroblastoma glycolipid extract compared to native
ch14.18, which suggests that the complex may have enhancedngth IgG molecules or scFv fragments. Anti-GD2 IgG templates have been used for
notoxins, targeted nanoparticles, and T-cell engaging bispeciﬁc antibodies (orange
T-cell engaging antibodies, and chimeric antigen receptors for adoptive cell therapy
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Alternatively, since IL-2 is known to bind to GD1b [63], a ganglio-
side expressed on neuroblastoma and sensory neurons and usually
extracted together with GD2, these IL-2 immunocytokines could
show enhanced tumor and tissue binding with altered biodistribu-
tion and unique toxicity proﬁles. The Ch14.18-IL-2 (‘CH3-IL2’) fu-
sion was shown to activate human effector cells [64] and more
effectively suppress xenografts compared to native ch14.18 anti-
body plus recombinant IL-2 [65]. To reduce potential immunoge-
nicity, a hu14.18-IL-2 fusion was engineered and used in Phase I
and II clinical trials [66,67], with a 21% response rate in patients
with minimal disease, but no response in patients with bulky dis-
ease of soft-tissue tumors [67,68]. Observed toxicities were similar
to what is observed with IL-2 alone, including capillary leak syn-
drome and abnormal liver functions [44,67]. Phase II clinical trial
of hu14.18-IL-2 for both melanoma (NCT00590824) [68] and for
neuroblastoma (NCT01334515) have been completed.
GM-CSF activates granulocytes and monocytes and has been
shown to have less side effects that IL-2, and an immunocytokine
based on GM-CSF and hu14.18 has also been reported [69]. GM-
CSF was fused to the C-terminus of the heavy chain of hu14.18
and showed signiﬁcantly enhanced in vitro ADCC compared to
antibody alone, or antibody in combination with recombinant
GM-CSF. No subsequent studies were reported as clinical develop-
ment has focused on hu14.18-IL-2 immunocytokine.
IL-15 is a cytokine that is structurally similar to IL-2 and acti-
vates NK, NKT and CD8(+) T-cells [70]; but unlike IL-2, it does
not cause capillary leak syndrome, precipitate activation induced
T cell death (AICD), or activate inhibitory regulatory T cells (Tregs),
as tested in non-human primates [71]. Because of its potential to
have less toxicity than IL-2, the anti-cancer properties of IL-15
are currently under investigation [70]. IL-15 and IL-2 both bind
to the same IL-2/IL-15 receptor b and c chains, but have their
own speciﬁc receptor a chains that confer speciﬁcity. Studies have
shown that the IL-15/IL-15Ra complex shows higher immune
stimulatory response than IL-15 alone [72–74]. Mortier et al. [75]
have shown that a fusion protein consisting of the sushi domain
of IL-15Ra (residues 1–77) linked to IL-15 (termed RLI) could have
higher functional activity than IL-15 alone or IL-15 in combination
with IL-15Ra. The same group recently created an anti-GD2 immu-
nocytokine where the IL-15 RLI fusion protein was linked to a
chimeric anti-GD2 antibody c.60C3 at the C-terminus of the heavy
chain [76]. In vitro assays showed that the c.60C3-RLI immunocy-
tokine had similar ADCC but enhanced CDC compared to the c60C3
alone, and in vivo mouse studies showed higher anti-tumor effects
than the antibody alone or the antibody in combination with
cytokine. While the higher complement activation may cause
enhanced pain side effects in patients, the higher tumor response
and potential to avoid capillary leak syndrome is encouraging.
3.2. Immunotoxins
Several attempts to fuse antibodies to protein toxins derived
from bacteria and plant sources have been made in an attempt to
increase the tumor killing potency of anti-GD2 antibodies. The
strategy relies on the ability of tumor targeting antibody to medi-
ate endocytosis of the attached toxin. Early investigation by War-
galla et al. [77] involved directly conjugating ricin-A chain toxin
(RA) to murine MoAb 14.G2a. Ricin is a ribosome inactivating pro-
tein that is composed of an A and B chain. The B chain can cause
non-speciﬁc toxicity, and as a result the A chain alone has been
used for antibody drug conjugates with some loss in potency.
The 14.G2-RA chemical conjugate at 1:1 molar ratio showed
in vitro cytotoxicity towards tumor cell lines that correlated with
GD2 expression and cellular uptake. Other toxin conjugates using
gelonin, a ribosome inactivating plant toxin [78] had the advantageof a utilizing a single polypeptide toxin molecule amenable to re-
combinant engineering. The chemically conjugated 14.G2a-gelonin
showed 1000-fold higher in vitro killing of melanoma cells than
gelonin alone, and also retained its ability to activate ADCC and
CMC.
In addition to these full length IgG-based constructs, immuno-
toxins have also been made using the anti-GD2 scFv of 5F11. Tho-
mas et al. [79] created a recombinant fusion protein of diphtheria
toxin A chain fused to 5F11 scFv. The resulting fusion protein was
able to directly and speciﬁcally kill GD2(+) tumor cells without Fc
mediated ADCC or CMC. Preliminary studies were also reported for
14.18 scFv recombinantly fused to pseudomonas exotoxin A, which
was also able to directly mediate killing of GD2(+) tumor cells
in vitro [55]. While immunotoxins showed promise in enhancing
GD2(+) tumor killing, a major concern has been the immunogenic-
ity associated with utilizing a foreign toxin protein. No GD2 based
immunotoxins are currently in human trials.
3.3. Antibody drug conjugates
The development of antibody-drug conjugates (ADCs), where
highly potent cytotoxic drugs are directly delivered to targeted
cancer cells, is an emerging ﬁeld with 2 FDA approved drugs cur-
rently in the market and over 20 candidates in clinical trials (see
Flygare et al. [80] for recent review). Antibody drug conjugates
consist of three components: the tumor targeting antibody, the
cytotoxic drug, and the linker that joins the two. Success of the
strategy depends on all three components to effectively bind to
the tumor target and have the complex endocytosed to the lyso-
some where the cytotoxic drug is selectively released inside the tu-
mor cell. Unlike immunotoxins, there is less concern over potential
immunogenicity, and ADCs have very high potency in the picomo-
lar range.
Current ADCs in clinical trials involve potent drugs that block
tubulin polymerization (auristatin and maytansine) or DNA dam-
aging agents (calicheamicin and duocarmycin). Lode et al. de-
scribed a calicheamicin analog conjugated to MoAb 14.G2a [81]
using disulﬁde formation between the drug and a chemically thio-
lated antibody. The 14.G2a-calicheamicin ADC was shown to sig-
niﬁcantly suppress liver metastasis in a syngeneic murine
neuroblastoma model. No follow up study with this or other
anti-GD2 ADC has been reported.
3.4. Radiolabeled antibodies
One of the ﬁrst therapeutic strategies attempted with MoAb 3F8
involved labeling with 131I for radioimmunotherapy (RIT) [82,83].
Neuroblastoma tumors are sensitive to radiation, and this ap-
proach of targeted radiation is a preferred approach to external
beam radiation, which can have high toxicity, especially with pedi-
atric patients. Pre-clinical evaluation have shown complete abla-
tion of neuroblastoma tumors that had been xenografted into
nude mice [82]. The maximum tolerated dose was established in
a Phase I trial in patients with neuroblastoma, and toxicities in-
cluded pain, fever, and rash, myelosuppression that required bone
marrow rescue, and hypothyroidism [84,85]. A second approach
utilizing 131I-3F8, involves the compartmental RIT of neuroblas-
toma metastatic to the brain or leptomeninges. This involves direct
injection of 131I-3F8 into the cerebral spinal ﬂuid via an intrathecal
or intraventricular catheter [86]. Compartmental RIT given in the
adjuvant setting has achieved a dramatic improvement in overall
survival compared to historical controls when this modality was
not available. Further trials of both strategies are ongoing.
Like many applications of RIT, the long serum half-life of MoAbs
(on the order of days) can lead to unwanted radiation damage to
the hematopoietic system and vital organs. In an effort to increase
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step targeting approach was taken using the anti-GD2 scFv 5F11
[53]. 5F11 was recombinantly fused to streptavidin, which formed
a homotetramer with enhanced avidity to GD2. Nude mice
xenografted with neuroblastoma tumors were ﬁrst given the
5F11-strepavidin protein, followed by a chemical clearing agent to
rapidly remove the unbound antibody protein. A small radioactive
ligand, 111In-DOTA (DOTA is a molecule that chelates radionuclides)
conjugated to biotin (111In-DOTA-biotin) was then injected as the
third step. The small 111In-DOTA-biotin (with afﬁnity of biotin for
the streptavidin at <1 pM) rapidly penetrated the tumor to bind
to the tumor-bound 5F11-stepavidin, while excess ligand under-
went rapid renal clearance. The results showed a signiﬁcantly
higher tumor-to-nontumor ratio compared to single step IgG
approach. Because of potential immunogenicity of streptavidin,
which is of bacterial origin, current strategies for multistep target-
ing involve full length hu3F8 IgG and anti-DOTA(metal) scFv as an
alternative to streptavidin [87], are currently under investigation.
3.5. Targeted nanoparticles
Nanoparticles offer the ability to carry large payloads (cytotoxic
drugs, RNA, contrast agents) for therapy or imaging of tumor cells.
Nanoparticles are generally 3–200 nm size particles composed of a
variety of materials including polymers, lipids, viruses, and organo-
metallic compounds (carbon nanotubes) [88].
Several studies have utilized lipid nanoparticles, in the form of
liposomes coupled to 14.G2a MoAbs or Fab fragments for targeting
(see Pastorino et al. [89] for recent review). One advantage of lipo-
some nanoparticles is their ability to extravasate through the leaky
capillaries of solid tumors, whereas the tight junctions of capillar-
ies in normal tissue limit their permeability [90–92]. Initial
attempts involved coupling full length 14.G2a antibodies to the
surface of liposomes carrying fenretidine [93], a derivative of 13-
cis-retinoic acid, a differentiating agent with efﬁcacy in neuroblas-
toma [94]. In vivo mouse studies of such liposomes did show
anti-tumor effect, although the ADCC effect of the antibody itself
could not be excluded. Subsequent studies by the same group
utilized the Fab fragment of MoAb 14.G2a to target liposome carriers,
which removed confounding effects of ADCC, while increasing
particle circulation time since Fab were not taken and recycled
by the reticuloendothelial system [95]. Anti-GD2 Fab fragments were
used to target liposome particles ﬁlled with a number of different
payloads including antisense oligonucleotides for the proto-onco-
genes c-myb [96] and c-myc [97], small interfering RNA for ana-
plastic lymphoma kinase (ALK) gene (which has been implicated
in neuroblastoma tumorigenesis) [98,99], and the chemotherapeu-
tic drug doxorubicin [100]. These strategies could decrease metas-
tases and prolong survival in mouse models. Another study by
Adrian et al. [101] utilized MoAb hu14.18 to target liposomes car-
rying siRNA against vascular endothelial growth factor A (VEGF-A),
showing in vitro data that VEGF-A could be selectively
downregulated.
Other nanoparticle formats have also been targeted using anti-
GD2 MoAbs. Tivnan et al. [102] recently utilized silica nanoparti-
cles, which may be more stable and inert than liposomes and can
carry larger payloads. The silica based nanoparticles were coupled
to MoAb ch14.18 and loaded with MicroRNA-34a, which targets
multiple cancer related genes, including MYCN, BCL2, SIRT1,
NOTCH1, JAG1, CCND1, CDK6, and E2F3. Mouse xenograft studies
showed tumor speciﬁc uptake of the targeted miR-34a loaded
nanoparticles and suppression of tumor growth relative to targeted
particles with no payload. Another strategy by Shen et al. [103] uti-
lized nanoparticles composed of polyethylene glycol and polyethy-
lenimine polymers coupled to iron oxide (for MRI imaging) and
MoAb 14.G2a, and loaded with siRNA that targets BCL2. Thesenanoparticles were able to selectively knockdown BCL2 activity,
which normally inhibits tumor cell apoptosis, and signiﬁcantly re-
duced neuroblastoma tumor growth in mice. Additional targeted
nanoparticle formats include recent reports where MoAb 14.G2a
was conjugated to carbon nanotubes [104] and gold nanorods
[105]. In vitro studies showed that these nanoparticles were able
to trigger photothermolysis of neuroblastoma cells under near-
infrared laser light exposure.
3.6. T-cell engaging bispeciﬁc antibodies (BsAb)
T cells are proven effectors, and releasing T cell checkpoints
with anti-CTLA4 and anti-PD1 or anti-PD1-L have shown beneﬁt
in melanoma [106,107]. However, for other less mutated and
non-carcinogen-induced, and hence less immunogenic human can-
cers, releasing T cell checkpoints while beneﬁcial is likely to be
insufﬁcient. In contrast to neuroblastoma, most adolescent or adult
cancers are less sensitive to killing mechanisms mediated by naked
IgG antibodies. And despite chemotherapy, surgery and radiation
therapy, these metastatic cancers tend to recur and lead to even-
tual death.
Based on the promising clinical success of antibodies that en-
gage T cells for cancer immunotherapy (such as Blinatumomab,
an anti-CD19 x anti-CD3 tandem scFv BsAb [108]), T cell-based
therapy is an area of enthusiastic research and development. We
have shown that T-cells can be effectively recruited to kill
GD2(+) cells using a chemically conjugated anti-GD2 x anti-CD3
bispeciﬁc antibody [109]. Both 5F11 and hu3F8 were successfully
engineered to form anti-CD3 BsAb. BsAb based on either IgG or
scFv are currently in development and show several log-fold in-
creases in tumor killing potency over conventional antibodies
(unpublished data). The clinical development of BsAb utilizing an
IgG based framework versus scFv format will depend on anti-tu-
mor response, serum half-life and potential toxicity related to
excessive cytokine release. Tandem scFv BsAb have serum half-
lives of minutes to hours, requiring continuous infusion, whereas
full-length antibodies can last in the blood for several days. The
ideal bispeciﬁc format for solid tumor immunotherapy has yet to
be established.
Another reported T-cell engaging bispeciﬁc antibody is TRBS07
(TRION Research, Germany). This trifunctional antibody utilized
mouse anti-GD2 antibody ME36.1. TRBS07 was made by a hy-
brid-hybridoma (quadroma) that produced a hybrid antibody with
monovalent binding to targets, carrying a specially engineered chi-
meric mouse IgG2a  rat IgG2b Fc region with preferential binding
to activating Fcc receptors (FccR) expressed on monocytes, macro-
phages, dendritic and natural killer cells [110,111]. Based on the
low afﬁnity monovalent binding to GD2, this therapeutic may be
developed for a vaccination strategy in patients rather than for re-
peat human use.
3.7. Chimeric antigen receptors (CAR)
An alternative approach to re-directing T-cells for tumor lysis is
to use chimeric antigen receptors (CAR) displayed on the surface of
the T-cells for adoptive cell therapy. Initial studies of ﬁrst genera-
tion GD2-speciﬁc CAR (using antibody 3G6) and retroviral trans-
fection showed that costimulatory signal was necessary [112].
Subsequent generations of CAR were built by Brenner and co-
workers using the scFv of MoAb 14.G2a as an extracellular domain
genetically fused to a transmembrane and intracellular domain of
CD28, OX40, and TCR f-chain. In vitro studies showed that these
CARmodiﬁed T cells could release cytokines, proliferate and kill tu-
mor cells [113]. Mouse xenograft studies showed tumor regression
and increased survival [114], and preliminary phase I study in pa-
tients with neuroblastoma showed persistence of the CAR modiﬁed
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Interestingly, the patients did not have the acute pain side-effects
associated with anti-GD2 whole antibody immunotherapy, which
may also signify that pain is complement mediated. More recent
preclinical studies have investigated the efﬁcacy of GD2-speciﬁc
CAR-modiﬁed T-cells for Ewing’s sarcoma [117], as well as the po-
tential of GD2-speciﬁc CAR for adoptive cell therapy using NK cells
[118,119].4. Conclusions and future directions
Over 20 years of clinical testing of anti-GD2 MoAbs have shown
that antibody immunotherapy is safe and can result in long term
survival for patients with high risk neuroblastoma. These antibod-
ies have been highly effective for non-bulky disease where patients
are treated in a minimal residual disease state. What has limited
the full utility of anti-GD2 immunotherapy has been the associated
pain toxicity and also the inability of most antibodies in general to
penetrate solid tumors.
For pain, several strategies have been proposed, including the
use of anti-O-acetyl-GD2 antibodies, or by using pathways that
bypass complement activation, such as using CMC-inactive Fc
domain, blocking reagents (Fc modiﬁed 3F8), T-cell engaging
bispeciﬁc antibodies, or adoptive T-cell therapy using GD2-speciﬁc
CAR. Future clinical trials are needed to verify which method is the
most effective. A better understanding of the antibody induced
pain pathways could uncover methods to alleviate them. Such pain
pathway information may also help design the next generation
anti-GD2 therapeutics, if they are going to be applied to the broad
spectrum of human cancers or conditions where GD2 is a target.
To increase the therapeutic index of anti-GD2 immunotherapy,
afﬁnity maturation while preserving GD2-speciﬁcity, as well as
multistep targeting strategies hold great promise. Beyond afﬁnity,
heightening effector functions using strategies reviewed here
(immunocytokines, immunotoxins, antibody drug conjugates, radi-
olabeled antibodies, targeted nanoparticles, bispeciﬁc T-cell engag-
ing antibodies, and chimeric antigen receptors) are being tested in
preclinical models. Antibodies utilize natural killer (NK) cells, neu-
trophils, and macrophages to carry out ADCC and CMC [19]. Unfor-
tunately, unlike neuroblastoma, most tumor types are relatively
insensitive to ADCC and CMC. Immunocytokines will subtly in-
crease the ADCC but will not dramatically enhance efﬁcacy. Anti-
bodies conjugated to toxins, drugs, radio-isotopes, and
nanoparticles can directly lead to tumor lysis, but all of these
methods carry potential added toxicity and immunogenicity. We
believe that the strategy with the greatest potential to transform
the ﬁeld in anti-GD2 immunotherapy will be the utilization of T-
cells using either bispeciﬁc antibodies or chimeric antigen
receptors.
T cells are the most effective immune cells for tumor lysis.
Although T cells are abundant and travel everywhere in the body,
their natural immunity towards human tumors is usually weak,
except for melanoma and renal cell tumors where mutations are
plentiful [120]. With few tumor-speciﬁc mutations, manipulating
immune checkpoints in pediatric cancer will be ineffective in
bringing about major anti-tumor effects. Even when immunity is
induced by man-made vaccines, the clonal frequencies of induced
tumor-speciﬁc T cells are typically low. Furthermore, tumors evade
T-cells by down-regulating human leukocyte antigen (HLA) and
up-regulating Tregs. Given these considerations, an opportunity ex-
ists to exploit the rich population of polyclonal T cells to kill tu-
mors selectively, bypassing the immunosuppressive tumor
microenvironment, while overcoming tumor cell HLA down-regu-
lation [121]. This approach has its own risk including the potential
to induce cytokine storms, but this hurdle has been overcome bymodulating doses as in the case of Blinatumomab. In our hands,
anti-GD2 T-cell engaging bispeciﬁc antibodies have resulted in
sub-femtomolar killing of several GD2(+) tumor cells in vitro and
in mouse xenograft models (unpublished), achieving a substantial
improvement in the anti-tumor response.
All of the strategies covered here represent a tremendous effort
to bring life-saving treatments to patients with a wide range of
tumors that all share this common glycolipid antigen. Many
anti-GD2 therapeutics are currently in clinical trials, with many
more in the pre-clinical stages. What has been demonstrated is
that these modalities not only reduce tumor burdens, but can also
result in cures for pediatric neuroblastoma patients. The challenge
will be to accelerate the clinical translation of these therapeutics in
patients with neuroblastoma while further reducing the dose and
intensity of cytotoxic chemotherapy or radiation therapy, and to
expand these potentially curative approaches to other pediatric
and adult solid tumors. What will ultimately lead to clinical
success depends on the therapeutics’ stability, tumor-killing
potency, immunogenicity, toxicity and acceptance by the oncology
community.
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